open access

Vol 2, No 2 (2011)
Review paper
Published online: 2011-07-15
Get Citation

Therapy of relapsed and refractory plasma cell myeloma

Krzysztof Jamroziak
Hematologia 2011;2(2):116-130.

open access

Vol 2, No 2 (2011)
REVIEW ARTICLES
Published online: 2011-07-15

Abstract

Introduction of novel active drugs including immunomodulatory agents and proteasome inhibitors to the therapy of plasma cell myeloma (PCM) significantly improved frequency and depth of clinical responses, and, most importantly, prolonged PCM patients’ survival. However, despite the important therapeutic advances, PCM remains a relapsing and incurable tumor. The aim of this paper was to discuss factors that influence the choice of optimal treatment strategy in relapsed or/and refractory PCM (r/rPCM). Moreover, the treatment options for r/rPCM were characterized with major attention paid to chemotherapy regimens based on thalidomide, lenalidomide, bortezomib or bendamustine. Furthermore, early-phase clinical trial results of newest promising drugs with potential to further improve prognosis of r/rPCM were briefly reviewed.
Hematologia 2011; 2, 2: 116–130

Abstract

Introduction of novel active drugs including immunomodulatory agents and proteasome inhibitors to the therapy of plasma cell myeloma (PCM) significantly improved frequency and depth of clinical responses, and, most importantly, prolonged PCM patients’ survival. However, despite the important therapeutic advances, PCM remains a relapsing and incurable tumor. The aim of this paper was to discuss factors that influence the choice of optimal treatment strategy in relapsed or/and refractory PCM (r/rPCM). Moreover, the treatment options for r/rPCM were characterized with major attention paid to chemotherapy regimens based on thalidomide, lenalidomide, bortezomib or bendamustine. Furthermore, early-phase clinical trial results of newest promising drugs with potential to further improve prognosis of r/rPCM were briefly reviewed.
Hematologia 2011; 2, 2: 116–130
Get Citation

Keywords

plasma cell myeloma; refractoriness; relapse; thalidomide; lenalidomide; bortezomib

About this article
Title

Therapy of relapsed and refractory plasma cell myeloma

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 2 (2011)

Article type

Review paper

Pages

116-130

Published online

2011-07-15

Bibliographic record

Hematologia 2011;2(2):116-130.

Keywords

plasma cell myeloma
refractoriness
relapse
thalidomide
lenalidomide
bortezomib

Authors

Krzysztof Jamroziak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.